Being a vet
is a work of Heart

Vetmedin Vet.
Contains **pimobendan**.
Indication: For the treatment of congestive heart failure in dogs caused by dilated cardiomyopathy (DCM) or valvular insufficiency, as well as for the preclinical treatment of DCM in Dobermann Pinschers and preclinical myxomatous mitral valve disease (MMVD) in dogs. The injection solution is used for the initial treatment of congestive heart failure. **Contraindications:**
Do not use in cases of hypertrophic cardiomyopathy, aortic stenosis, or hypersensitivity to the active substance or excipients. Oral solution and chewable tablets must not be used in cases of severely impaired liver function. **Precautions:** Use with caution in dogs with impaired liver function and diabetes mellitus. Cardiac function should be monitored during treatment. Avoid contact with skin and eyes when using the oral solution. Chewable tablets are flavored and should be kept out of reach of animals. **Adverse Reactions:** Rare side effects include vomiting, diarrhea, anorexia, lethargy, increased heart rate, and increased mitral regurgitation. Very rare side effects include petechiae and subcutaneous bleeding. **Dosage:** *Oral solution and chewable tablets:* 0.5 mg pimobendan/kg body weight per day, divided into two doses approximately 12 hours apart. Administer about 1 hour before feeding. Tablets can be split for accurate dosing. *Injection solution:* Single intravenous treatment with 0.15 mg pimobendan/kg body weight. **Marketing Authorisation Holder:** Boehringer Ingelheim Vetmedica GmbH. **Further Information:**Boehringer Ingelheim Animal Health Nordics A/S, Weidekampsgade 14, 2300 Copenhagen S, Denmark. Detailed information about this veterinary medicinal product can be found in the EU medicines database: https://medicines.health.europa.eu/veterinary

SPC Dates: Injection solution: 2024, Oral solution: 2025, Chewable tablets: 2024/2025

Boehringer
Ingelheim